White House Drug Strategy Asserts Federal Authority Over Hemp-Derived THC, Targets Delta-8 as Schedule I
The biennial report from the Office of National Drug Control Policy signals that enforcement against intoxicating hemp products will intensify before the November ban takes effect.
By CBDWorldNews Editorial Staff | May 27, 2026
The Trump administration released the 2026 National Drug Control Strategy on May 4, and the hemp industry got a clearer picture of where federal enforcement is heading. The biennial report, prepared by the White House Office of National Drug Control Policy (ONDCP), dedicates significant attention to hemp-derived cannabinoids — framing them alongside fentanyl and methamphetamine as part of a broader drug control agenda.
Delta-8 and Beyond: Named as Schedule I
The strategy document is explicit: delta-8 THC, delta-10 THC, THC-O, THCP, and related analogues are classified as Schedule I controlled substances. While the 2018 Farm Bill created a legal gray area that allowed these compounds to proliferate, the administration contends that the FY2026 appropriations language closed that loophole.
The ONDCP describes these compounds as “unregulated psychoactive derivatives of hemp” and notes that while the hemp plant naturally contains small amounts of delta-8 THC, the commercial products sold across the country are typically manufactured through chemical conversion processes in laboratories.
This distinction matters. The strategy draws a line between hemp as an agricultural crop and hemp-derived intoxicating products as a drug enforcement concern. The government’s position is that manufacturing processes that convert CBD isolate into delta-8 or other THC analogues produce controlled substances, regardless of the starting material.
“New Legal Authority” Claimed
The administration states it has been granted “new legal authority” through the agriculture funding bill to address psychoactive hemp-derived substances. The ONDCP frames this as part of a whole-of-government approach to intensify prosecution of illicit drug production and distribution.
The language is broad. The strategy calls for heightened scrutiny of companies manufacturing, distributing, and selling products that contain synthetic or semi-synthetic cannabinoids. It also references the forthcoming November 12 effective date for the hemp product restrictions as a clear enforcement milestone.
“Psychoactive derivatives of hemp are a growing concern.” — 2026 National Drug Control Strategy, ONDCP
What This Means for CBD Companies
For companies selling traditional CBD products — oils, topicals, capsules — the immediate threat depends on formulation. Full-spectrum CBD products that contain naturally occurring trace amounts of THC could face scrutiny under the 0.4-milligram-per-container threshold.
Broad-spectrum and isolate-based products that contain no measurable THC are less directly affected. But the administration’s broad language about “hemp-derived cannabinoid products” has created anxiety across the supply chain.
The ONDCP strategy doesn’t differentiate between a CBD wellness product and a delta-8 gummy in its rhetoric. Both fall under the umbrella of “hemp-derived” products that the government views as insufficiently regulated. For CBD businesses, this rhetorical conflation is its own form of risk — it shapes public perception, retailer willingness to stock products, and payment processor decisions.
Companies that invest in third-party testing and COA verification are better positioned to demonstrate compliance, but the regulatory framework itself remains in flux.
Texas Adds State-Level Pressure
The federal strategy landed the same week as a related state development. On May 1, the Texas Supreme Court cleared the way for the state Department of State Health Services to classify delta-8 THC as a Schedule I controlled substance.
The court lifted a temporary injunction that had blocked DSHS enforcement since 2021. While the ruling acknowledged that hemp businesses were harmed by the classification, justices determined that the DSHS commissioner had the authority to make the scheduling decision.
Texas represents one of the largest markets for hemp-derived THC products in the country. The combination of federal and state enforcement actions creates a pincer effect that leaves manufacturers and retailers with shrinking legal ground.
Industry Response
Hemp industry advocates have pushed back against the ONDCP’s framing. Trade groups argue that lumping CBD and hemp-derived THC products alongside illicit drugs misrepresents the industry and ignores the millions of consumers who use these products without incident.
Some advocates point to a seeming contradiction in the administration’s own position. President Trump has separately called on Congress to “fix” the law imposing the hemp product ban, suggesting the White House recognizes that the blanket prohibition may be too broad.
For consumers researching CBD product options, the practical advice is straightforward: verify that products carry current lab testing results, understand whether a product contains any THC, and monitor federal and state regulatory developments as November approaches.
These statements have not been evaluated by the Food and Drug Administration. CBD products are not intended to diagnose, treat, cure, or prevent any disease.
